Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.62 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.62 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | DRD5 | P21918 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29586758 | 1.00 | CYP4F2 (0.62) | CYP4F2CYP4A11ESR1ESR2DRD2 | |
| SCHEMBL9838425 | 1.00 | CYP4F2 (0.62) | CYP4F2CYP4A11ESR1ESR2DRD2 | |
| SCHEMBL9837746 | 1.00 | CYP4F2 (0.62) | CYP4F2CYP4A11ESR1ESR2DRD2 | |
| SCHEMBL10508228 | 0.90 | CYP4F2 (0.73) | CYP4F2CYP4A11ESR1ESR2 | |
| SCHEMBL12660944 | 0.88 | CYP4F2 (0.64) | CYP4F2CYP4A11 | |
| SCHEMBL31562259 | 0.86 | CYP4F2 (0.49) | CYP4F2CYP4A11 | |
| SCHEMBL1044067 | 0.86 | CYP4F2 (0.61) | CYP4F2CYP4A11 | |
| SCHEMBL20730230 | 0.86 | CYP4F2 (0.68) | CYP4F2CYP4A11DRD2DRD3 | |
| SCHEMBL1020122 | 0.86 | CYP4F2 (0.61) | CYP4F2CYP4A11 | |
| SCHEMBL6631393 | 0.86 | CYP4F2 (0.61) | CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240051931-A1 | HDAC INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-02-15 | — | — | US | disclosed |
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| WO-2022120048-A1 | HDAC INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022120048-A1 | HDAC INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-06-09 | — | — | WO | disclosed |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2021-04-29 | — | — | US | disclosed |
| WO-2020162612-A1 | PYRIDINE COMPOUND SUBSTITUTED BY HETEROARYL | 大正製薬株式会社 | 2020-08-13 | — | — | WO | disclosed |
| EP-3666766-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| CN-110914254-A | Azole-substituted pyridine compound | 大正制药株式会社 | 2020-03-24 | — | — | CN | disclosed |
| EP-2885285-B1 | PYRAZOLE DRIVATIVES WHICH INHIBIT LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2016-10-19 | — | — | EP | disclosed |
| US-9403830-B2 | Inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-02 | — | — | US | disclosed |
| WO-2002026729-A2 | BENZOPYRANCARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS | MERCK & CO., INC. (US) | 2002-04-04 | — | — | WO | disclosed |
| EP-0533695-B1 | IMIDAZO (4,5-c) PYRIDINES WITH PAF ANTAGONIST ACTIVITY | PFIZER (US) | 1994-10-05 | — | — | EP | disclosed |
| US-5322847-A | Inhibit platelet activating factor, block leukotriene D4 receptors | PFIZER INC. (US) | 1994-06-21 | — | — | US | disclosed |
| EP-0533695-A1 | IMIDAZO (4,5-c) PYRIDINES WITH PAF ANTAGONIST ACTIVITY. | PFIZER (US) | 1993-03-31 | — | — | EP | disclosed |
| CN-1057839-A | The azepine benzoglyoxaline that is used for the treatment of asthma, sacroiliitis and relative disease | PFIZER (US) | 1992-01-15 | — | — | CN | disclosed |
| WO-1991017163-A1 | IMIDAZO (4,5-c) PYRIDINES WITH PAF ANTAGONIST ACTIVITY | PFIZER INC. (US) | 1991-11-14 | — | — | WO | disclosed |
| US-5037747-A | Production of benzopyran-2-carboxylic acids and esters by enzymatic hydrolysis | HOFFMANN-LA ROCHE INC. (US) | 1991-08-06 | — | — | US | disclosed |
| US-4788214-A | ANTIALLERGENS | HOFFMAN-LA ROCHE INC. (US) | 1988-11-29 | — | — | US | disclosed |
| US-4785017-A | ANTIALLERGENS | HOFFMANN-LA ROCHE INC. (US) | 1988-11-15 | — | — | US | disclosed |
| EP-0129906-B1 | PHENOXYALKOXY-3,4-DIHYDRO-2H-1-BENZOPYRAN DERIVATIVES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1988-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | CYP2C19, CYP4A11, CYP11B1 | CYP4F2 20/4885CYP4A11 2/4885ESR1 892/4885 |
| US-11365192-B2 | Pyridine compound substituted with azole | CYP2C19, CYP4A11, CYP11B1 | CYP4F2 20/4885CYP4A11 2/4885ESR1 892/4885 |
| US-20240051931-A1 | HDAC INHIBITORS | HDAC8, HDAC1, HDAC2 | CYP4F2 4724/4885CYP4A11 3805/4885ESR1 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.